15 years of experience with HIFU using Ablatherm technology

A media release issued by EDAP TMS SA — the developer and distributor of the Ablatherm® technology used in high-intensity focused ultrasound (HIFU) treatment of men with prostate cancer — states that a review of 15 years experience with Ablatherm technology will be published in the June issue  of Current Urology Reports. … READ MORE …

Epigenetics and prostate cancer revisited

We have commented before on the potential of epigenetics in the development of innovative therapies for the management of prostate cancer. … READ MORE …

“Is there an optimal management for localized prostate cancer?”

Most knowledgeable prostate cancer advocates and educators know that the answer to this question is “No.” The correct answer is that the management of localized prostate cancer needs to take account of the characteristics, objectives, and expectations of each individual patient, including his overall health and quality of life. … READ MORE …

Proton beam radiation: a systematic review

A recent article in the Annals of Internal Medicine, commissioned by the Agency for Healthcare Research and Quality (AHRQ) and carried out by investigators at the Tufts Medical Center Evidence-based Practice Center in Boston, concludes that “Evidence on the comparative effectiveness and safety of charged-particle radiation therapy in cancer is needed to assess the benefits, risks, and costs of treatment alternatives.” … READ MORE …

Perspectives on the first-line treatment of localized prostate cancer

A series of review articles and editorials on the first-line treatment of prostate cancer has started this month in the journal Oncology. Additional articles will appear in the October issue of the journal. The full text of all articles is available on line at no cost. … READ MORE …